---
document_datetime: 2025-12-29 10:42:26
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/rizmoic.html
document_name: rizmoic.html
version: success
processing_time: 0.1125214
conversion_datetime: 2025-12-30 09:36:39.647746
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Rizmoic

[RSS](/en/individual-human-medicine.xml/67179)

##### Authorised

This medicine is authorised for use in the European Union

naldemedine Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Rizmoic](#news-on)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Rizmoic is a medicine for treating constipation caused by opioid pain relief medicines in patients who have previously been treated with a laxative (a medicine that triggers bowel movements).

It contains the active substance naldemedine.

Expand section

Collapse section

## How is Rizmoic used?

Rizmoic is available as 200 microgram tablets. The recommended dose is one tablet once daily, which the patient can take with or without a laxative.

The patient must stop taking Rizmoic when they are no longer taking an opioid. Rizmoic can only be obtained with a prescription. For more information about using Rizmoic, see the package leaflet or contact your doctor or pharmacist.

## How does Rizmoic work?

The active substance in Rizmoic, naldemedine, works by attaching to and blocking receptors in the gut (mu-, delta- and kappa-opioid receptors), through which opioid medicines cause constipation.

Because molecules of naldemedine were designed not be able to enter into the brain, the medicine does not block opioids from working on pain receptors in the brain and therefore does not interfere with pain relief.

## What benefits of Rizmoic have been shown in studies?

Studies have shown that Rizmoic is effective at improving bowel movement in patients who are currently taking laxatives or had taken laxatives in the past.

The studies compared Rizmoic with placebo (a dummy treatment) to see if treatment would consistently increase the number of patients who can pass stools and allow them to do so at least 3 times a week during treatment.

In two of the studies, involving 1095 patients taking opioids for chronic (long-term) pain caused by a condition other than cancer, 50% of patients taking Rizmoic for 12 weeks achieved the desired outcome, compared with 34% of patients taking placebo.

In two other  studies, involving 307 patients taking opioids for cancer pain, 74% of patients taking Rizmoic for two weeks achieved the desired outcome compared with 36% of patients taking placebo.

## What are the risks associated with Rizmoic?

The most common side effects with Rizmoic in patients without cancer (which may affect up to 1 in 10 people) are abdominal pain (belly ache), diarrhoea, nausea and vomiting. In patients with cancer, the most common side effects were diarrhoea (seen in more than 1 in 10 people) and abdominal pain (seen in up to 1 in 10 people). The majority of side effects in patients with or without cancer were mild to moderate.

Rizmoic must not be used in patients with a blocked or perforated bowel or patients at high risk of bowel blockage. For the full list of side effects and restrictions, see the package leaflet.

## Why is Rizmoic authorised in the EU?

Constipation is the most common side effect of opioid pain medicines and many standard laxatives are not effective in treating the condition.

Rizmoic has been shown to improve bowel movement in patients taking opioids pain medicines for long-term pain (including cancer pain). Furthermore, the side effects of Rizmoic, which mainly affected the gut, were mostly mild or moderate.

The European Medicines Agency therefore decided that Rizmoic's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Rizmoic?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rizmoic have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Rizmoic are continuously monitored. Side effects reported with Rizmoic are carefully evaluated and any necessary action taken to protect patients.

## Other information about Rizmoic

Rizmoic received a marketing authorisation valid throughout the EU on 18 February 2019.

Rizmoic : EPAR - Medicine overview

Reference Number: EMA/21684/2019

English (EN) (73.92 KB - PDF)

**First published:** 01/03/2019

**Last updated:** 06/03/2019

[View](/en/documents/overview/rizmoic-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-406)

български (BG) (98.23 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

06/03/2019

[View](/bg/documents/overview/rizmoic-epar-medicine-overview_bg.pdf)

español (ES) (73.77 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

06/03/2019

[View](/es/documents/overview/rizmoic-epar-medicine-overview_es.pdf)

čeština (CS) (97.58 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

06/03/2019

[View](/cs/documents/overview/rizmoic-epar-medicine-overview_cs.pdf)

dansk (DA) (72.01 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

06/03/2019

[View](/da/documents/overview/rizmoic-epar-medicine-overview_da.pdf)

Deutsch (DE) (74.28 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

06/03/2019

[View](/de/documents/overview/rizmoic-epar-medicine-overview_de.pdf)

eesti keel (ET) (80.47 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

06/03/2019

[View](/et/documents/overview/rizmoic-epar-medicine-overview_et.pdf)

ελληνικά (EL) (97.77 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

06/03/2019

[View](/el/documents/overview/rizmoic-epar-medicine-overview_el.pdf)

français (FR) (74.27 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

06/03/2019

[View](/fr/documents/overview/rizmoic-epar-medicine-overview_fr.pdf)

hrvatski (HR) (89.87 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

06/03/2019

[View](/hr/documents/overview/rizmoic-epar-medicine-overview_hr.pdf)

italiano (IT) (72.19 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

06/03/2019

[View](/it/documents/overview/rizmoic-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (94.55 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

06/03/2019

[View](/lv/documents/overview/rizmoic-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (93.86 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

06/03/2019

[View](/lt/documents/overview/rizmoic-epar-medicine-overview_lt.pdf)

magyar (HU) (92.4 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

06/03/2019

[View](/hu/documents/overview/rizmoic-epar-medicine-overview_hu.pdf)

Malti (MT) (96.52 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

06/03/2019

[View](/mt/documents/overview/rizmoic-epar-medicine-overview_mt.pdf)

Nederlands (NL) (72.11 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

06/03/2019

[View](/nl/documents/overview/rizmoic-epar-medicine-overview_nl.pdf)

polski (PL) (96.09 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

06/03/2019

[View](/pl/documents/overview/rizmoic-epar-medicine-overview_pl.pdf)

português (PT) (73.72 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

06/03/2019

[View](/pt/documents/overview/rizmoic-epar-medicine-overview_pt.pdf)

română (RO) (92.96 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

06/03/2019

[View](/ro/documents/overview/rizmoic-epar-medicine-overview_ro.pdf)

slovenčina (SK) (95.55 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

06/03/2019

[View](/sk/documents/overview/rizmoic-epar-medicine-overview_sk.pdf)

slovenščina (SL) (90.64 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

06/03/2019

[View](/sl/documents/overview/rizmoic-epar-medicine-overview_sl.pdf)

Suomi (FI) (72.09 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

06/03/2019

[View](/fi/documents/overview/rizmoic-epar-medicine-overview_fi.pdf)

svenska (SV) (77.74 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

06/03/2019

[View](/sv/documents/overview/rizmoic-epar-medicine-overview_sv.pdf)

Rizmoic : EPAR - Risk-management-plan summary

English (EN) (167.75 KB - PDF)

**First published:** 01/03/2019

[View](/en/documents/rmp-summary/rizmoic-epar-risk-management-plan-summary_en.pdf)

## Product information

Rizmoic : EPAR - Product information

English (EN) (558.61 KB - PDF)

**First published:** 01/03/2019

**Last updated:** 10/12/2025

[View](/en/documents/product-information/rizmoic-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-332)

български (BG) (652.16 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

10/12/2025

[View](/bg/documents/product-information/rizmoic-epar-product-information_bg.pdf)

español (ES) (537.82 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

10/12/2025

[View](/es/documents/product-information/rizmoic-epar-product-information_es.pdf)

čeština (CS) (678.61 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

10/12/2025

[View](/cs/documents/product-information/rizmoic-epar-product-information_cs.pdf)

dansk (DA) (614.78 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

10/12/2025

[View](/da/documents/product-information/rizmoic-epar-product-information_da.pdf)

Deutsch (DE) (644.76 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

10/12/2025

[View](/de/documents/product-information/rizmoic-epar-product-information_de.pdf)

eesti keel (ET) (666.69 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

10/12/2025

[View](/et/documents/product-information/rizmoic-epar-product-information_et.pdf)

ελληνικά (EL) (618.54 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

10/12/2025

[View](/el/documents/product-information/rizmoic-epar-product-information_el.pdf)

français (FR) (581.43 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

10/12/2025

[View](/fr/documents/product-information/rizmoic-epar-product-information_fr.pdf)

hrvatski (HR) (562.03 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

10/12/2025

[View](/hr/documents/product-information/rizmoic-epar-product-information_hr.pdf)

íslenska (IS) (551.51 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

10/12/2025

[View](/is/documents/product-information/rizmoic-epar-product-information_is.pdf)

italiano (IT) (565.9 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

10/12/2025

[View](/it/documents/product-information/rizmoic-epar-product-information_it.pdf)

latviešu valoda (LV) (640.21 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

10/12/2025

[View](/lv/documents/product-information/rizmoic-epar-product-information_lv.pdf)

lietuvių kalba (LT) (606.39 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

10/12/2025

[View](/lt/documents/product-information/rizmoic-epar-product-information_lt.pdf)

magyar (HU) (616.58 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

10/12/2025

[View](/hu/documents/product-information/rizmoic-epar-product-information_hu.pdf)

Malti (MT) (724.1 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

10/12/2025

[View](/mt/documents/product-information/rizmoic-epar-product-information_mt.pdf)

Nederlands (NL) (541.82 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

10/12/2025

[View](/nl/documents/product-information/rizmoic-epar-product-information_nl.pdf)

norsk (NO) (526.07 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

10/12/2025

[View](/no/documents/product-information/rizmoic-epar-product-information_no.pdf)

polski (PL) (606.8 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

10/12/2025

[View](/pl/documents/product-information/rizmoic-epar-product-information_pl.pdf)

português (PT) (573.21 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

10/12/2025

[View](/pt/documents/product-information/rizmoic-epar-product-information_pt.pdf)

română (RO) (619.05 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

10/12/2025

[View](/ro/documents/product-information/rizmoic-epar-product-information_ro.pdf)

slovenčina (SK) (624.34 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

10/12/2025

[View](/sk/documents/product-information/rizmoic-epar-product-information_sk.pdf)

slovenščina (SL) (603.88 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

10/12/2025

[View](/sl/documents/product-information/rizmoic-epar-product-information_sl.pdf)

Suomi (FI) (535.17 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

10/12/2025

[View](/fi/documents/product-information/rizmoic-epar-product-information_fi.pdf)

svenska (SV) (579.17 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

10/12/2025

[View](/sv/documents/product-information/rizmoic-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000315032 10/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Rizmoic : EPAR - All authorised presentations

English (EN) (193.72 KB - PDF)

**First published:** 01/03/2019

**Last updated:** 19/06/2025

[View](/en/documents/all-authorised-presentations/rizmoic-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-367)

български (BG) (137.06 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

19/06/2025

[View](/bg/documents/all-authorised-presentations/rizmoic-epar-all-authorised-presentations_bg.pdf)

español (ES) (128.82 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

19/06/2025

[View](/es/documents/all-authorised-presentations/rizmoic-epar-all-authorised-presentations_es.pdf)

čeština (CS) (131.03 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

19/06/2025

[View](/cs/documents/all-authorised-presentations/rizmoic-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (128.31 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

19/06/2025

[View](/da/documents/all-authorised-presentations/rizmoic-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (128.56 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

19/06/2025

[View](/de/documents/all-authorised-presentations/rizmoic-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (128.94 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

19/06/2025

[View](/et/documents/all-authorised-presentations/rizmoic-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (134.01 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

19/06/2025

[View](/el/documents/all-authorised-presentations/rizmoic-epar-all-authorised-presentations_el.pdf)

français (FR) (128.25 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

19/06/2025

[View](/fr/documents/all-authorised-presentations/rizmoic-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (130.89 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

19/06/2025

[View](/hr/documents/all-authorised-presentations/rizmoic-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (130.29 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

19/06/2025

[View](/is/documents/all-authorised-presentations/rizmoic-epar-all-authorised-presentations_is.pdf)

italiano (IT) (129.65 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

19/06/2025

[View](/it/documents/all-authorised-presentations/rizmoic-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (134.14 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

19/06/2025

[View](/lv/documents/all-authorised-presentations/rizmoic-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (132.61 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

19/06/2025

[View](/lt/documents/all-authorised-presentations/rizmoic-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (133.35 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

19/06/2025

[View](/hu/documents/all-authorised-presentations/rizmoic-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (132.91 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

19/06/2025

[View](/mt/documents/all-authorised-presentations/rizmoic-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (127.25 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

19/06/2025

[View](/nl/documents/all-authorised-presentations/rizmoic-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (130.69 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

19/06/2025

[View](/no/documents/all-authorised-presentations/rizmoic-epar-all-authorised-presentations_no.pdf)

polski (PL) (129.63 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

19/06/2025

[View](/pl/documents/all-authorised-presentations/rizmoic-epar-all-authorised-presentations_pl.pdf)

português (PT) (129.36 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

19/06/2025

[View](/pt/documents/all-authorised-presentations/rizmoic-epar-all-authorised-presentations_pt.pdf)

română (RO) (131.75 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

19/06/2025

[View](/ro/documents/all-authorised-presentations/rizmoic-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (133.89 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

19/06/2025

[View](/sk/documents/all-authorised-presentations/rizmoic-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (131.81 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

19/06/2025

[View](/sl/documents/all-authorised-presentations/rizmoic-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (126.28 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

19/06/2025

[View](/fi/documents/all-authorised-presentations/rizmoic-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (126.46 KB - PDF)

**First published:**

01/03/2019

**Last updated:**

19/06/2025

[View](/sv/documents/all-authorised-presentations/rizmoic-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Rizmoic Active substance naldemedine tosilate International non-proprietary name (INN) or common name naldemedine Therapeutic area (MeSH) Constipation Anatomical therapeutic chemical (ATC) code A06AH05

### Pharmacotherapeutic group

- Drugs for constipation
- Peripheral opioid receptor antagonists

### Therapeutic indication

Rizmoic is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have previously been treated with a laxative.

## Authorisation details

EMA product number EMEA/H/C/004256 Marketing authorisation holder

Shionogi B.V.

Herengracht 464

Opinion adopted 13/12/2018 Marketing authorisation issued 18/02/2019 Revision 13

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Rizmoic : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (155.07 KB - PDF)

**First published:** 19/06/2025

**Last updated:** 10/12/2025

[View](/en/documents/procedural-steps-after/rizmoic-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Rizmoic : EPAR - Procedural steps taken and scientific information after the authorisation (archive)

English (EN) (130.53 KB - PDF)

**First published:** 29/08/2019

**Last updated:** 19/06/2025

[View](/en/documents/procedural-steps-after/rizmoic-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Rizmoic-H-C-PSUSA-00010753-201903 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/687390/2019

English (EN) (131.59 KB - PDF)

**First published:** 19/12/2019

[View](/en/documents/scientific-conclusion/rizmoic-h-c-psusa-00010753-201903-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Rizmoic : EPAR - Public assessment report

Reference Number: EMA/466/2019

English (EN) (7.99 MB - PDF)

**First published:** 01/03/2019

[View](/en/documents/assessment-report/rizmoic-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Rizmoic

Adopted

Reference Number: EMA/845509/2018

English (EN) (67.56 KB - PDF)

**First published:** 14/12/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-rizmoic_en.pdf)

#### News on Rizmoic

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018) 14/12/2018

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 10/12/2025

## Share this page

[Back to top](#main-content)